For laboratory research only
Compare LL-37 research suppliers
Listings now default to lowest tracked price per mg. The highlighted price badge is a catalog-price signal only, not a quality, safety, or documentation ranking.
The document count covers six basic checks. “Not found” means we could not confirm it from the public records we reviewed—not that the testing never happened.
Affiliate disclosure: Some links may earn PDD a commission. Affiliate status does not change what we report or how suppliers are ordered.
Ascend Science
6 of 6 fields documentedReview recommendedLL-37 (10 mg)
Exact name catalog match · Affiliate relationship · Price badge is not an overall recommendation
Listed price
$75.00
$7.50 per mg
Est. with PDD: $63.75
$6.38/mg
In stock
Eppix Labs
5 of 6 fields documentedReview recommendedLL-37 (5 mg)
Exact name catalog match · No active affiliate relationship
Listed price
$39.99
$8.00 per mg
In stock
Ameano Peptides
1 of 6 fields documentedPossibly outdatedLL-37 (10 mg)
Exact name catalog match · No active affiliate relationship
Listed price
$80.00
$8.00 per mg
In stock
Ascension Peptides
2 of 6 fields documentedPossibly outdatedLL-37 (10 mg)
Exact name catalog match · Affiliate relationship
Listed price
$89.00
$8.90 per mg
In stock
Particle Peptides
2 of 6 fields documentedReview recommendedLL-37 (5 mg)
Exact name catalog match · Affiliate relationship · Price badge is not an overall recommendation
Listed price
€65.03
€13.01 per mg
In stock
How LL-37 is used in research
LL-37 is generated from the human cathelicidin precursor and has been studied for membrane interactions, microbial effects, immune signaling, chemotaxis, and wound-related biology.
Its activity can vary with salt concentration, serum, peptide aggregation, cell type, and assay conditions. It can also produce cytotoxic or pro-inflammatory effects in some systems.
Evidence map
Research stage matters. Findings from one model should not be silently promoted to another.
Laboratory
Extensive cell and microbiology studies examine membrane and immune effects.
Animal
Infection, inflammation, and wound models have been reported.
Human
The biology is clinically relevant, but LL-37 is not an approved therapeutic peptide.
What the evidence does not establish
In-vitro antimicrobial activity may not predict activity in complex biological fluids. Results can reverse across concentration and context.
Study findings also do not authenticate a supplier’s material. Biological plausibility, a familiar name, or a published paper cannot substitute for lot-specific identity and quality evidence.
Analytical and documentation checks
The test plan should match the exact molecule, modification, and research question.
- Verify sequence, termini, and disulfide status where applicable.
- Consider aggregation and adsorption during assay design.
- Document endotoxin controls because immune assays are especially sensitive to contamination.
At minimum, connect the product name, sequence, sample identifier, lot, report, method, expected result, and observed result. Record untested attributes as “not reported,” not as assumed passes.
Build the documentation record
Regulatory status
LL-37 is not an FDA-approved drug.
Regulatory status can change and attaches to specific products and jurisdictions. Verify current official records before publishing, procuring, or relying on a status claim.
Primary sources and official records
Use these records as starting points, then assess the exact model, test article, methods, and date:
Peptide Due Diligence Research Brief
Follow the evidence, not the headline.
Receive new evidence maps, documentation guides, and material corrections as the directory expands.
By subscribing, you agree to receive PDD research emails. Unsubscribe at any time.
Already subscribed? Get your free checklist.